BioRestorative Therapies (BRTX) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 28, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 12,835,315
Trading Symbol	BRTX
Entity Common Stock, Shares Outstanding		3,925,818

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 166,555	$ 91,798
Accounts receivable	93,375	0
Prepaid expenses and other current assets	29,348	22,515
Total Current Assets	289,278	114,313
Property and equipment, net	643,087	493,856
Intangible assets, net	1,038,741	1,037,732
Security deposit	45,900	45,900
Total Assets	2,017,006	1,691,801
Current Liabilities:
Accounts payable	2,549,042	1,111,879
Accrued expenses and other current liabilities	2,046,795	1,466,506
Accrued interest	6,823	94,026
Current portion of notes payable, net of debt discount of $150,286 and $113,257 at December 31, 2015 and 2014, respectively	1,009,797	5,688,239
Deferred revenues	0	164,349
Total Current Liabilities	5,612,457	8,524,999
Accrued interest, non-current portion	11,011	5,195
Notes payable, non-current portion, net of debt discount of $7,999 and $0 at December 31, 2015 and 2014, respectively	302,001	50,000
Total Liabilities	$ 5,925,469	$ 8,580,194
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at December 31, 2015 and 2014	$ 0	$ 0
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued 3,338,661 and 1,725,596 shares at December 31, 2015 and 2014, respectively; Outstanding 3,310,729 and 1,697,664 shares at December 31, 2015 and 2014, respectively	3,339	1,726
Additional paid-in capital	29,443,704	18,541,907
Accumulated deficit	(33,323,506)	(25,400,026)
Treasury stock, at cost, 27,932 shares at December 31, 2015 and 2014	(32,000)	(32,000)
Total Stockholders' Deficiency	(3,908,463)	(6,888,393)
Total Liabilities and Stockholders' Deficiency	$ 2,017,006	$ 1,691,801

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current portion of notes payable, debt discount (in dollars)	$ 150,286	$ 113,257
Non-current portion of notes payable, debt discount (in dollars)	$ 7,999	$ 0
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, Authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, Authorized	30,000,000	30,000,000
Common stock, Issued	3,338,661	1,725,596
Common stock, Outstanding	3,310,729	1,697,664
Treasury stock, at cost, shares	27,932	27,932

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues	$ 628,915	$ 415,996
Cost of sales	261,504	213,834
Gross Profit	367,411	202,162
Operating Expenses
Marketing and promotion	168,352	125,626
Consulting	1,394,037	1,310,121
Research and development	2,105,059	1,430,614
General and administrative	3,870,325	2,258,307
Total Operating Expenses	7,537,773	5,124,668
Loss From Operations	(7,170,362)	(4,922,506)
Other (Expense) Income
Interest expense	(263,583)	(285,275)
Amortization of debt discount	(339,443)	(464,470)
Loss on extinguishment of notes payable, net	(35,677)	(49,094)
Warrant modification expense	(114,415)	(50,035)
Gain on settlement of payables	0	183,768
Total Other Expense	(753,118)	(665,106)
Net Loss	$ (7,923,480)	$ (5,587,612)
Net Loss Per Share
- Basic and Diluted (in dollars per share)	$ (3.20)	$ (4.38)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted (in shares)	2,472,889	1,276,904

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Treasury Stock
Beginning Balance at Dec. 31, 2013	$ (6,685,069)	$ 982	$ 13,158,363	$ (19,812,414)	$ (32,000)
Beginning Balance (in shares) at Dec. 31, 2013		981,662			(27,932)
Shares and warrants issued for cash	2,605,000	$ 434	2,604,566	0	$ 0
Shares and warrants issued for cash (in shares)		433,600			0
Shares issued in satisfaction of accrued consulting services	140,000	$ 30	139,970	0	$ 0
Shares issued in satisfaction of accrued consulting services (in shares)		29,773			0
Shares and warrant issued as payment for leasehold improvements	71,050	$ 14	71,036	0	$ 0
Shares and warrant issued as payment for leasehold improvements (in shares)		14,210			0
Exercise of warrants for purchase of common stock	113,000	$ 19	112,981	0	$ 0
Exercise of warrants for purchase of common stock (in shares)		18,834			0
Conversion of notes payable and accrued interest into common stock	359,711	$ 89	359,622	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		89,239			0
Shares and warrants issued in exchange of note payable and accrued interest	343,026	$ 55	342,971	0	$ 0
Shares and warrants issued in exchange of note payable and accrued interest (in shares)		55,073			0
Shares and warrants issued in connection with extension of notes payable	249,800	$ 50	249,750	0	$ 0
Shares and warrants issued in connection with extension of notes payable (in shares)		50,000			0
Warrant modifications	50,035	$ 0	50,035	0	$ 0
Beneficial conversion features related to convertible notes payable	92,370	0	92,370	0	0
Stock-based compensation: - common stock	300,784		300,784		0
Stock-based compensation: - options and warrants	1,059,512	$ 53	1,059,459	0	$ 0
Stock-based compensation: - options and warrants (in shares)		53,205			0
Net loss	(5,587,612)	$ 0	0	(5,587,612)	$ 0
Ending Balance at Dec. 31, 2014	(6,888,393)	$ 1,726	18,541,907	(25,400,026)	$ (32,000)
Ending Balance (in shares) at Dec. 31, 2014		1,725,596			(27,932)
Shares and warrants issued for cash	2,033,700	$ 395	2,033,305	0	$ 0
Shares and warrants issued for cash (in shares)		395,425			0
Exercise of warrants for purchase of common stock	264,144	$ 76	264,068	0	$ 0
Exercise of warrants for purchase of common stock (in shares)		75,473			0
Conversion of notes payable and accrued interest into common stock	238,508	$ 54	238,454	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		53,595			0
Shares issued in satisfaction of accrued services	8,481	$ 1	8,480	0	$ 0
Shares issued in satisfaction of accrued services (in shares)		943			0
Shares and warrants issued in connection with settlement agreement	152,000	$ 4	151,996	0	$ 0
Shares and warrants issued in connection with settlement agreement (in shares)		4,230			0
Shares and warrants issued as debt discount in connection with notes payable	178,893	$ 10	178,883	0	$ 0
Shares and warrants issued as debt discount in connection with notes payable (in shares)		10,000			0
Shares and warrants issued in exchange of note payable and accrued interest	5,755,872	$ 1,028	5,754,844	0	$ 0
Shares and warrants issued in exchange of note payable and accrued interest (in shares)		1,028,237			0
Warrant modifications	229,288	$ 0	229,288	0	$ 0
Beneficial conversion features related to convertible notes payable	87,788	0	87,788	0	0
Stock-based compensation: - common stock	177,647	$ 44	177,603	0	$ 0
Stock-based compensation: - common stock (in shares)		43,698			0
Stock-based compensation: - options and warrants	1,777,089	$ 0	1,777,089	0	$ 0
Stock-based compensation: - options and warrants (in shares)		0
Impact of share rounding as a result of reverse stock split	0	$ 1	(1)
Impact of share rounding as a result of reverse stock split (in shares)		1,464
Net loss	(7,923,480)	$ 0	0	(7,923,480)	0
Ending Balance at Dec. 31, 2015	$ (3,908,463)	$ 3,339	$ 29,443,704	$ (33,323,506)	$ (32,000)
Ending Balance (in shares) at Dec. 31, 2015		3,338,661			(27,932)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows From Operating Activities
Net loss	$ (7,923,480)	$ (5,587,612)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	339,443	464,470
Accretion of interest expense	85,086	24,934
Depreciation and amortization	213,784	96,685
Loss on sale of property and equipment	0	1,009
Stock-based compensation	1,954,736	1,360,296
Loss on extinguishment of note payables, net	35,677	49,094
Gain on settlement of payables	0	(183,768)
Inventory write-down	0	15,407
Warrant modification expense	114,415	50,035
Changes in operating assets and liabilities:
Accounts receivable	(93,375)	0
Prepaid expenses and other current assets	(6,833)	11,832
Security deposit	0	(45,900)
Accounts payable	1,381,407	(234,563)
Accrued interest	(81,387)	585,881
Accrued expenses and other current liabilities	1,022,813	0
Deferred revenues	(164,349)	164,349
Total Adjustments	4,801,417	2,359,761
Net Cash Used In Operating Activities	(3,122,063)	(3,227,851)
Cash Flows From Investing Activities
Purchases of property and equipment	(408,069)	(168,376)
Proceeds from sale of property and equipment	0	980
License maintenance costs	(75,000)	0
Net Cash Used In Investing Activities	(483,069)	(167,396)
Cash Flows From Financing Activities
Proceeds from notes payable	1,210,015	795,000
Repayments of notes payable	(5,000)	(202,063)
Advances from director, officer and family member of officer	564,105	58,054
Repayment of advances from director and officer	(387,075)	(83,044)
Proceeds from exercise of warrants	264,144	113,000
Sales of common stock and warrants for cash	2,033,700	2,605,000
Net Cash Provided By Financing Activities	3,679,889	3,285,947
Net Increase (Decrease) In Cash	74,757	(109,300)
Cash - Beginning	91,798	201,098
Cash - Ending	166,555	91,798
Cash paid during the period for:
Interest	61,453	127,112
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	238,508	359,711
Accrued interest reclassified as principal in connection with note payable reissuance	44,379	108,059
Beneficial conversion features set up as debt discount	87,788	92,370
Advances converted into note payable, related party	65,000	0
Indebtedness satisfied via legal settlement	5,000	0
Accrued liabilities associated with purchases of property and equipment	139,729	258,774
Warrant modifications in connection with extension of notes payable and setup as debt discount
Non-cash investing and financing activities:
Stock Issued	114,873	0
Shares and warrants issued in connection with issuance or extension of notes payable
Non-cash investing and financing activities:
Stock Issued	178,893	249,800
Shares and warrants issued in exchange for notes payable and accrued interest
Non-cash investing and financing activities:
Stock Issued	5,720,195	343,026
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Stock Issued	8,481	140,000
Shares and warrants issued in connection with settlement agreement
Non-cash investing and financing activities:
Stock Issued	152,000	0
Shares and warrant issued as payment for lease oblication and leasehold improvements
Non-cash investing and financing activities:
Stock Issued	$ 0	$ 71,050

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which was formed in the Cayman Islands (collectively, “BRT” or the “Company”). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com www.stempearls.com Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split 200,000,000 30,000,000

Going Concern and Management's

Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2015
Development Stage Enterprise [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management’s Plans As of December 31, 2015, the Company had a working capital deficiency and a stockholders’ deficiency of $ 5,323,179 3,908,463 7,923,480 5,587,612 The Company's primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to December 31, 2015, the Company has received aggregate equity financing (including proceeds from the exercise of common stock purchase warrants) and debt financing of $ 1,831,270 325,000 80,156 163,000 103,500 310,000 13,172 514,518

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss. Two pharmaceutical clients comprised substantially all of the Company’s revenue during the years ended December 31, 2015 and 2014. See Revenue Recognition – Research and Development Agreements below. The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts, periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 5 The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 17.7 The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses. Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. Payment terms were (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015. During the year ended December 31, 2015, the final deliverable pursuant to the research and development agreement was completed and delivered. Through December 31, 2015, the full $ 250,000 ($ 134,281 115,719 On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $ 250,000 688,892 1,733 773,267 ($ 475,209 298,058 84,375 On March 1, 2016, the Company received the final payment 80,156 4,219 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. On November 30, 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the years ended December 31, 2015 and 2014, the Company recognized $ 19,000 0 During the years ended December 31, 2015 and 2014, the Company recognized revenue related to sales of Stem Pearls skincare products of $ 425 2,219 The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2015 and 2014. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations. Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. December 31, 2015 2014 Options 1,330,450 779,200 Warrants 1,066,930 412,422 Convertible notes 148,708 32,695 Total potentially dilutive shares 2,546,088 1,224,317 The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTCQB Marketplace. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Advertising costs are charged to operations as incurred. For the years ended December 31, 2015 and 2014, the Company incurred advertising costs of $ 23,467 15,280 Research and development expenses are charged to operations as incurred. For the years ended December 31, 2015 and 2014, the Company incurred research and development expenses of $ 2,105,059 1,430,614 The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk. The Company bifurcates When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. To allow entities additional time to implement systems, gather data and resolve implementation questions, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, in August 2015, to defer the effective date of ASU No. 2014-09 for one year, which is fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements or disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and annual and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this new standard will have on its financial statement disclosures. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 amends the existing guidance to require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related debt liability instead of as a deferred charge. ASU 2015-03 is effective on a retrospective basis for annual and interim reporting periods beginning after December 15, 2015; earlier adoption is permitted. Additionally, in August 2015 the FASB issued guidance expanding the April 2015 update (ASU No. 2015-15). It states that, given the absence of authoritative guidance within the update, the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset for revolving lines of credit and subsequently amortizing the deferred debt issuance costs ratably over the term of the arrangement, regardless of whether there are any outstanding borrowings on the line of credit. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years, with early adoption permitted for financial statements that have not been previously issued. Full retrospective application is required. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The FASB issued ASU 2015-17 as part of its ongoing Simplification Initiative, with the objective of reducing complexity in accounting standards. The amendments in ASU 2015-17 require entities that present a classified balance sheet to classify all deferred tax liabilities and assets as a noncurrent amount. This guidance does not change the offsetting requirements for deferred tax liabilities and assets, which results in the presentation of one amount on the balance sheet. Additionally, the amendments in ASU 2015-17 align the deferred income tax presentation with the requirements in International Accounting Standards (IAS) 1, Presentation of Financial Statements. The amendments in ASU 2015-17 are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 4 – Property and Equipment, net December 31, 2015 2014 Office equipment $ 9,494 $ 8,466 Medical equipment 418,280 359,248 Furniture and fixtures 126,150 113,874 Computer software and equipment 85,118 66,458 Leasehold improvements 301,610 103,582 940,652 651,628 Less: accumulated depreciation (297,565) (157,772) Property and equipment, net $ 643,087 $ 493,856 Depreciation expense amounted to $ 139,793 26,872

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2015
Disclosure Intangible Assets [Abstract]
Intangible Assets	Note 5 – Intangible Assets On January 27, 2012, the Company entered into a license agreement with the SCTC (as amended on March 21, 2012 and November 30, 2015, the “SCTC Agreement”). On April 6, 2012 (the “Closing Date”), the Company and SCTC closed on the SCTC Agreement. Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from SCTC to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. On March 5, 2015, the Company made a $ 75,000 225,000 475,000 Patents and Accumulated Trademarks Licenses Amortization Total Balance as of January 1, 2014 $ 3,676 $ 1,226,500 $ (122,631) $ 1,107,545 Amortization expense - - (69,813) (69,813) Balance as of December 31, 2014 3,676 1,226,500 (192,444) 1,037,732 Additions - 75,000 - 75,000 Amortization expense - - (73,991) (73,991) Balance as of December 31, 2015 $ 3,676 $ 1,301,500 $ (266,435) $ 1,038,741 Weighted average remaining amortization period at December 31, 2015 in years 5.0 13.9 Patents and Accumulated Trademarks Licenses Amortization Balance as of January 1, 2014 $ 1,104 $ 121,527 $ 122,631 Amortization expense 368 69,445 69,813 Balance as of December 31, 2014 1,472 190,972 192,444 Amortization expense 368 73,623 73,991 Balance as of December 31, 2015 $ 1,840 $ 264,595 $ 266,435 Amortization expense is reflected in general and administrative expenses in the consolidated statements of operations. Based upon the current intangible assets as of December 31, 2015, amortization expense is projected to be approximately $ 75,000

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 6 – Accrued Expenses and Other Current Liabilities December 31, 2015 2014 Credit card payable $ 3,171 $ 4,739 Accrued payroll 1,010,633 679,277 Advances from related parties 87,030 - Accrued purchases of property and equipment - 174,801 Accrued research and development expenses 446,175 292,395 Accrued general and administrative expenses 456,182 315,294 Deferred rent 43,604 - Total $ 2,046,795 $ 1,466,506 During the year ended December 31, 2015, the Company received an aggregate of $ 564,105 387,075 65,000 75,000 October 30, 2015 (see Note 7) 25,000 6,250 14,063 6,250 4.00 11,063 During the year ended December 31, 2015, the Company recognized a $ 126 58,054 83,044

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2015
Notes Payable [Abstract]
Notes Payable	Note 7 – Notes Payable Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, January 1, 2014 $ 4,000,000 $ 281,000 $ 1,473,500 $ (240,491) $ 5,514,009 Issuances 500,000 300,000 [1] - - 800,000 Exchanges for equity - (71,000) (203,000) - (274,000) Conversions to equity - (342,500) - - (342,500) Repayments (89,063) - (113,000) - (202,063) Recognition of debt discount - - - (347,170) [1] (347,170) Amortization of debt discount - - - 464,470 464,470 Recharacterization of accrued interest as principal - - 108,059 [3] - 108,059 Accretion of interest expense - 15,000 [2] - 9,934 [1] 24,934 Settlement of accreted interest - (7,500) [2] - - (7,500) Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 [4] $ 1,265,559 $ (113,257) $ 5,738,239 Issuances 150,000 735,000 [1] 478,018 [1] - 1,363,018 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (266,667) (877,873) - (5,555,477) Conversion to equity - (223,333) - - (223,333) Repayments - - (5,000) - (5,000) Recognition of debt discount - - - (469,557) [1] (469,557) Accretion of interest expense - - - 85,086 [1] 85,086 Amortization of debt discount - - - 339,443 339,443 Recharacterization of accrued interest as principal - - 44,379 [3] - 44,379 Outstanding, December 31, 2015 $ 150,000 $ 420,000 [4] $ 900,083 $ (158,285) $ 1,311,798 [1] During the years ended December 31, 2015 and 2014, notes with an aggregate principal amount of $ 538,018 30,000 450,015 25,000 88,003 5,000 75,000 65,000 [2] During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 June 10, 2014 90,000 105,000 15,000 7,500 January 8, 2014 30,000 [3] During the years ended December 31, 2015 and 2014, in connection with the extension of certain notes payable, an aggregate of $ 44,379 108,059 [4] As of December 31, 2015 and 2014, convertible notes with an aggregate principal balance of $ 420,000 175,000 197,500 83,333 Bermuda Lender On May 8, 2014, Cayman borrowed an additional $ 500,000 15 89,063 On August 13, 2014, Cayman and the Bermuda Lender agreed to extend the maturity date of a $ 4,000,000 July 31, 2014 December 31, 2014 27,500 121,000 On December 31, 2014, Cayman and the Bermuda Lender agreed to further extend the maturity date of the $4,000,000 Bermuda Lender Note from December 31, 2014 June 30, 2015 22,500 99,000 On May 11, 2015, Cayman and the Bermuda Lender agreed to extend the maturity date of the $ 500,000 410,938 May 7, 2015 June 30, 2015 316,297 On May 27, 2015, the Company and the Bermuda Lender agreed to exchange the $500,000 Bermuda Lender Note and the $4,000,000 Bermuda Lender Note with an aggregate principal amount of $ 4,410,937 69,436 746,730 3,733,645 186,682 15.00 672,056 40,000 December 31, 2015 80,000 5,327 On October 9, 2015, the Company borrowed $ 150,000 150,000 10 March 9, 2016 239,182 15.00 4.00 98,739 As of December 31, 2015 and 2014, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock. Convertible Notes and Other Notes Issuances Between January 17, 2014 and May 2, 2014, the Company issued convertible notes with an aggregate principal amount of $ 175,000 170,000 30,000 25,000 5,000 145,000 12 The convertible notes were initially payable 3-12 months from the date of issuance 175,000 145,000 Between November 12, 2014 and December 2, 2014, the Company issued convertible notes in the aggregate principal amount of $ 125,000 10 41,667 41,667 41,666 (a) 60% of the fair value of the Company’s stock or (b) $1.00 per share. In the event that the Company elects to effect a conversion of a specific note during the five day period following the conversion, the holder of that note shall have the right to convert the remaining outstanding principal amount of the convertible note, together with accrued and unpaid interest thereon, into shares of the Company’s common stock at a conversion price equal to the conversion price in the Company-effected conversion During the year ended December 31, 2015, the Company issued convertible notes with an aggregate principal balance of $ 735,000 725,000 1 12 10,000 (a) a range of 55% to 65% of the fair value of the Company's common stock or (b) $2.00 or $3.00 per share depending on the note. In the event that the Company elects to convert a portion of the $272,500 of principal outstanding under the notes into common stock, the holder will have the right to convert the remaining principal into shares of common stock at the same conversion price. In connection with the issuance of the convertible notes, the Company issued five-year, immediately vested warrants to purchase an aggregate of 30,885 shares of common stock at exercise prices ranging from $5.00 to $10.00 per share. 90,018 During the year ended December 31, 2015, the Company issued other notes payable with an aggregate principal amount of $ 478,018 400,015 75,000 65,000 78,003 Conversions, Exchanges and Other During the year ended December 31, 2014, the Company elected to convert certain convertible notes with an aggregate principal balance of $ 225,000 13,565 60,138 2.80 5.60 During the year ended December 31, 2014, the holders of certain convertible notes elected to convert such convertible notes with an aggregate principal balance of $ 117,500 3,646 29,102 3.80 4.40 During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $ 71,000 4,260 12,339 5,000 15.00 74,029 1,231 During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain other notes with an aggregate principal balance of $ 203,000 15,672 42,735 5,000 exercise price of $ 15.00 268,997 50,323 In connection with the extension of other notes during the year ended December 31, 2014, the Company issued five-year warrants to purchase an aggregate of 9,500 10.00 15.00 29,800 During the year ended December 31, 2015, the Company elected to convert certain convertible notes with an aggregate principal balance of $ 223,333 15,175 53,595 3.00 5.16 During the year ended December 31, 2015, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $ 266,667 12,580 92,875 39,092 exercise price of $ 4.00 288,060 8,813 During the year ended December 31, 2015, the Company and certain lenders agreed to exchange certain other notes with an aggregate principal balance of $ 877,873 82,701 188,632 111,358 4.00 15.00 982,112 21,537 As of December 31, 2015, the Company reclassified principal in the aggregate amount of $ 302,001 7,999 11,011 During the year ended December 31, 2015, the Company extended certain other notes payable in the aggregate principal amount of $ 735,081 10,000 37,500 4.00 88,875 35,215 10.00 4.00 10,234 During the years ended December 31, 2015 and 2014, the Company repaid an aggregate principal balance of $ 5,000 113,000 During the years ended December 31, 2015 and 2014, the contingently adjustable conversion ratios associated with certain convertible notes were resolved. The Company estimated the intrinsic value of the embedded conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the years ended December 31, 2015 and 2014 the Company recognized $ 87,788 92,370 As of December 31, 2015, the outstanding convertible notes have maturity dates ranging from January 2016 to June 2016 and predominantly bear interest at a rate of 10 As of December 31, 2015, the outstanding other notes have maturity dates ranging from past due to October 2016 and predominantly bear interest at a rate of 15 2.0 4.0

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	For The Years Ended December 31, 2015 2014 United States $ (7,767,924) $ (5,223,749) Foreign (155,556) (363,863) Loss before income taxes $ (7,923,480) $ (5,587,612) The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below: For The Years Ended December 31, 2015 2014 Deferred Tax Assets: Net operating loss carryforward $ 1,181,900 $ 4,820,500 Stock-based compensation 1,976,600 1,272,600 Accruals 231,100 240,700 Research & development tax credits 139,480 95,500 Other 2,100 2,100 Gross deferred tax assets 3,531,180 6,431,400 Deferred Tax Liabilities: Fixed assets (110,300) (93,200) Intangible assets (13,400) (8,100) Gross deferred tax liabilities (123,700) (101,300) Net deferred tax assets 3,407,480 6,330,100 Valuation allowance (3,407,480) (6,330,100) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ (2,922,620) $ (43,500) For The Years Ended December 31, 2015 2014 Federal: Current $ - $ - Deferred 2,614,976 38,921 State and local: Current - - Deferred 307,644 4,579 2,922,620 43,500 Change in valuation allowance (2,922,620) (43,500) Income tax provision (benefit) $ - $ - For The Years Ended December 31, 2015 2014 Tax benefit at federal statutory rate (34.0) % (34.0) % State income taxes, net of federal benefit (4.0) % (4.0) % Permanent differences 0.8 % 0.8 % Research & development tax credits (0.6) % (1.8) % Impact of Section 382 limit 76.0 % 41.2 % True-ups and other (0.6) % (1.4) % Change in valuation allowance (37.6) % (0.8) % Effective income tax rate 0.0 % 0.0 % The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized. At December 31, 2015 and 2014, the Company had approximately $ 3,100,000 12,700,000 The net operating loss carry forwards, if not utilized, will expire from 2029 to 2035 for federal purposes 50 approximately $15,500,000 and $5,700,000, respectively, of federal NOLs not being realizable the reversal of approximately $5,900,000 and $2,200,000, respectively, of net operating loss deferred tax assets The Company has filed income tax returns in the U.S. federal jurisdiction and the states of Florida and New York.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Operating Lease Jupiter, Florida Lease The Company was a party to a three year lease agreement with respect to premises located in Jupiter, Florida, which was scheduled to expire on January 31, 2014 6,234 6,422 On February 4, 2014, the Company and the landlord agreed to the surrender of a portion of the leased premises and also extended the term of the lease to July 31, 2014. The amended lease provided for a base rent of $ 962 Melville, New York Lease On August 25, 2014, the Company entered into a lease for 6,800 132,600 149,260 In connection with the Melville Lease, the Company paid the landlord a security deposit of $ 45,900 14,210 7,105 10.00 (i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease. 71,050 60,000 11,050 Summary Rent expense amounted to $ 141,131 20,380 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. 4,230 30,000 7.60 12.00 152,000 The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Research Agreements On May 9, 2014, the Company entered into an amendment to a research agreement (the “Research Agreement”) with the research foundation of a state university (the “University”). Pursuant to the amendment, the parties agreed that (i) no fees were payable by the Company to the University pursuant to the Research Agreement for the first five scheduled monthly payments in 2014 ($ 208,335 41,667 20,000 323,336 166,668 During the years ended December 31, 2015 and 2014, the Company recorded research and development expense of approximately $ 103,000 264,000 112,000 43,000 Consulting Agreements Marketing Consulting Services On June 27, 2014, a February 17, 2011 agreement for marketing consulting services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Marketing Consulting Term”). In consideration of services rendered during the New Marketing Consulting Term and the settlement of the Company’s obligation to pay $ 65,000 25,000 12,500 20.00 110,000 37,500 0 82,500 Consulting Services On February 20, 2014, the Company executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become the Company’s Chief Medical Advisor for Spine Medicine pursuant to which he oversees the clinical aspects of the brtxDISC Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive $ 10,000 20,000 15,000 13.00 67,830 15,000 20,000 25,000 6.40 124,200 180,000 115,000 On March 12, 2014, as additional compensation for consulting services rendered, the Company granted to a consultant an immediately vested, five-year warrant to purchase 5,000 10.60 14,000 10.60 30.00 1,000 23,270 30,096 On July 23, 2014, the Company entered into a one-year agreement with a consultant to market research and development arrangements and other business transactions to potential strategic partners and other alliance candidates. In exchange for services provided by the consultant during the term, the Company agreed to issue 1,500 10,500 7,500 49,800 33,000 On October 7, 2014, the Company entered into an agreement with a consultant for services regarding the search for a President for the Company’s Disc/Spine Division. The consultant was entitled to an initial retainer fee of $ 15,000 10,000 28 25,000 2,420 15,000 59,000 10,000 Business Advisory Services On June 27, 2014, a February 17, 2011 agreement for business advisory services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Business Advisory Term”). In consideration of services rendered during the New Business Advisory Term, the Company agreed to pay a cash fee of $ 16,667 12,500 20.00 37,500 75,000 15,000 15,000 5,000 10.00 17,000 15,000 10,000 12.00 10,000 10.00 74,923 180,000 150,000 Scientific Advisory Services On March 14, 2014, the Company executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, the Company immediately granted the new advisor a five-year option to purchase 1,250 10.00 625 625 250 5,860 On June 27, 2014, an August 16, 2012 consulting agreement for scientific advisory services was further extended to August 16, 2016 such that the consultant will continue to serve as Chairman of the Company’s Scientific Advisory Board, will earn $ 10,000 15,000 5.70 7,500 7,500 81,000 120,000 120,000 Employment Agreements Chief Executive Officer On October 23, 2014, the Company and its Chief Executive Officer (“CEO”) approved amendments to the employment agreement between the Company and the CEO, dated October 4, 2010, as amended, providing for (a) a reduction of the CEO’s annual salary from $ 600,000 450,000 450,000 400,000 Pursuant to the amendment, the CEO would still be entitled to an annual bonus equal to 50% of his annual salary and an annual car allowance of $28,800 On March 9, 2015, the Company and its CEO agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum and, effective January 1, 2015, the CEO’s annual car allowance was reduced to $14,400 from $28,800. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied 100,000 300,000 723,800 614,400 As of December 31, 2015 and 2014, the accrued and unpaid compensation (salary, bonus, tax liability, car allowance and vacation pay) for the CEO was $ 797,576 574,278 Other On February 9, 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and bonus. In the event the Company terminates the Division President without cause, the Division President is entitled to cash severance payments equal to one-half of his then annual base salary (such one-half amount is currently $ 150,000 25,000 9.20 200,400 On March 9, 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount is currently $ 125,000 As of December 31, 2015, two other employees have “at-will” employment agreements with the Company that provide for aggregate cash severance payments of $ 175,000 Board of Directors On June 27, 2014, a director of the Company resigned due to other business commitments. In consideration of director services performed to date, the Company agreed to pay an aggregate of $ 80,000 30,000 50,000 96,250 As of December 31, 2015 and 2014, $ 200,000 105,000 Related Party Agreement Effective October 1, 2014, the Company entered into a three-month agreement with an affiliate of one of its then directors for consulting services related to the Company’s brtxDISC Program and ThermoStem Program. Pursuant to the agreement, the affiliate of the director was entitled to a cash fee of $ 10,000 5,000 1,725 1,840 15,000 15,000

Stockholders' Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 10 – Stockholders’ Deficiency Authorized Capital On December 19, 2014, the Company’s stockholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware effective January 1, 2015 and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 200,000,000 1,000,000 5,000,000 Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split 200,000,000 30,000,000 As of December 31, 2015, the Company was authorized to issue 30,000,000 0.001 5,000,000 0.01 2010 Equity Participation Plan On February 18, 2014 and October 23, 2014, the Board of Directors of the Company approved successive increases in the number of shares of common stock authorized to be issued pursuant to the Plan from 300,000 600,000 1,000,000 1,000,000 On September 4, 2015, the Compensation Committee of the Board increased the number of shares authorized to be issued pursuant to the Plan from 1,000,000 2,000,000 2,250,000 2,250,000 Common Stock and Warrant Offerings During the year ended December 31, 2014, the Company issued an aggregate of 433,600 5.00 9.00 2,605,000 116,535 6.00 15.00 389,608 During the year ended December 31, 2015, the Company issued an aggregate of 395,425 4.00 7.00 2,033,700 (of such aggregate issuances, 50,000 300,000 259,464 5.00 15.00 12,500 15.00 40,000 611,730 125,000 125,000 5.00 500,000 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0 5 Warrant Exercises On November 27, 2013, the Company initiated a limited time program which, at the election of any warrant holder, would permit them to immediately exercise their outstanding exercisable warrants at an exercise price of $ 6.00 15.00 The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $25.00 for five consecutive trading days. 18,833 113,000 50,035 During the year ended December 31, 2015, warrants to purchase an aggregate of 75,473 3.50 4.00 15.00 264,144 21,865 21,865 20,295 Stock Warrants For The Years Ended December 31, 2015 2014 Risk free interest rate 1.29% - 1.75 % 0.39% - 2.20 % Expected term (years) 5.00 1.96 - 5.00 Expected volatility 120% - 122 % 116% - 122 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the years ended December 31, 2015 and 2014 was approximately $ 2.72 3.40 See Note 7 – Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 10 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings. During the year ended December 31, 2015, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 47,939 470,085 6.00 20.00 4.00 10.00 77,905 The Company recorded stock–based compensation expense of $ 99,501 185,266 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2015 412,422 $ 17.97 [1] Compensatory grants 65,000 8.85 Investor grants 664,981 9.14 Exercised (75,473) 3.50 [2] Forfeited - - Outstanding, December 31, 2015 1,066,930 $ 7.56 [1][3] 3.9 $ 150,651 Exercisable, December 31, 2015 1,031,930 $ 7.56 [3] 4.0 $ 150,651 [1] Excludes the impact of a warrant to purchase 35,000 30.00 [2] During the year ended December 31, 2015, warrants to purchase an aggregate of 75,473 4.00 15.00 3.50 [3] During the year ended December 31, 2015, warrants to purchase an aggregate of 527,308 5.00 20.00 4.00 Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 602,603 3.9 602,603 $5.00 - $5.99 138,500 4.9 138,500 $6.00 - $9.99 58,750 4.5 58,750 $10.00 - $14.99 74,732 4.3 74,732 $15.00 - $19.99 98,687 3.8 98,687 $20.00 - $80.00 58,658 1.7 58,658 Variable [1] 35,000 - - 1,066,930 4.0 1,031,930 [1] A warrant to purchase 35,000 30.00 Stock Options For the Years Ended December 31, 2015 2014 Risk free interest rate 1.33% - 2.24 % 1.13% - 2.66 % Expected term (years) 5.00 - 10.00 5.00 - 10.00 Expected volatility 120% - 123 % 132% - 135 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the stock options granted during the years ended December 31, 2015 and 2014 was approximately $ 4.07 5.40 See Note 9 – Commitments and Contingencies for details associated with certain grants of options as compensation to employees, directors and consultants. On September 4, 2015, the Compensation Committee of the Board determined that, with respect to all outstanding options granted under the Plan, to the extent not already provided for in the stock option agreement evidencing the option grant, the optionee be given the right to exercise the option on a cashless basis as contemplated by Section 13(b) of the Plan and, other than in the case of the Company’s CEO, in the event of a termination of employment, directorship, consultancy or membership on the Company’s Scientific Advisory Board, to the extent that the options are then exercisable, they shall remain exercisable until twelve months following such termination (unless the stock option agreement evidencing the option grant provides that such options are exercisable until the expiration date of the options), but in no event shall the options be exercisable after the respective expiration dates of the options. Weighted Average Remaining For The Years Ended Unrecognized at Amortization December 31, December 31, Period 2015 2014 2015 (Years) Consulting $ 595,446 $ 365,825 $ 755,416 2.3 Research and development 376,596 328,740 793,450 [1] 2.2 General and administrative 705,546 179,628 1,037,552 2.2 $ 1,677,588 $ 874,193 $ 2,586,418 2.2 [1] Includes $ 191,403 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2015 779,200 $ 12.18 Granted 586,250 7.14 Exercised - - Forfeited (35,000) 6.34 Outstanding, December 31, 2015 1,330,450 $ 10.11 8.4 $ - Exercisable, December 31, 2015 679,577 $ 12.56 7.9 $ - The following table presents information related to stock options at December 31, 2015: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $4.40 - $6.99 368,750 8.3 131,250 $7.00 - $9.99 574,250 9.5 209,125 $10.00 - $19.99 202,000 7.4 160,752 $20.00 - $30.00 185,450 6.1 178,450 1,330,450 7.9 679,577 Compensatory Common Stock Issuances See Note 9 – Commitments and Contingencies for details associated with certain issuances of common stock as compensation to employees, directors and consultants. Between June 27, 2014 and December 31, 2014, the Company issued 7,500 33,000 During the years ended December 31, 2015, the Company issued an aggregate of 31,473 112,847 During the year ended December 31, 2015, the Company issued 943 8,481 For The Years Ended Unrecognized at December 31, December 31, 2015 2014 2015 Consulting $ 168,800 $ 276,500 $ - Research and development 8,847 24,337 - $ 177,647 $ 300,837 $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 11 - Subsequent Events Short Term Advances Subsequent to December 31, 2015, the Company received $ 46,030 99,560 Notes Payable On February 18, 2016, the Company issued a one-year note payable with a principal amount of $ 250,000 10 20,000 4.00 On March 7, 2016, the Company issued a convertible note with a principal amount of $ 75,000 10 The convertible note is payable as follows: (i) $25,000 of principal and the respective accrued interest is payable six months from the issuance date (the “First Maturity Date”), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date, and (iii) $25,000 of principal and the respective accrued interest on such principal is payable one month following the First Maturity Date. Each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) 62% of the fair market value of the Company’s stock or (b) $2.00 per share. Subsequent to December 31, 2015, the Company elected to convert certain convertible notes with an aggregate principal balance of $ 150,000 7,370 52,457 3.00 Subsequent to December 31, 2015, the Company and a certain lender agreed to exchange certain other notes with an aggregate principal balance of $ 160,000 5,802 78,955 2.10 Subsequent to December 31, 2015, the Company extended the maturity date of a note payable in the principal amount of $ 163,000 30,000 25,000 5,000 Subsequent to December 31, 2015 (excluding amounts repaid as discussed above) the Company repaid an aggregate principal amount of $ 78,500 Common Stock and Warrant Offerings Subsequent to December 31, 2015, the Company issued an aggregate of 404,593 1,248,937 4.50 5.00 1,618,372 Stock-Based Compensation Subsequent to December 31, 2015, the Company issued an aggregate of 18,253 Subsequent to December 31, 2015, the Company granted a ten-year option to purchase 15,000 3.70 Warrant Exercises Subsequent to December 31, 2015, warrants to purchase an aggregate of 60,831 3.50 4.00 15.00 212,898 Warrant Modifications Subsequent to December 31, 2015, the Company reduced the exercise price of warrants to purchase an aggregate of 12,916 15.00 4.00

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss
Concentrations and Credit Risk	Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the years ended December 31, 2015 and 2014. See Revenue Recognition – Research and Development Agreements below.
Cash	The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts, periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 5 The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.
Intangible Assets	Intangible Assets Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 17.7
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses.
Revenue Recognition	Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. Payment terms were (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015. During the year ended December 31, 2015, the final deliverable pursuant to the research and development agreement was completed and delivered. Through December 31, 2015, the full $ 250,000 ($ 134,281 115,719 On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $ 250,000 688,892 1,733 773,267 ($ 475,209 298,058 84,375 On March 1, 2016, the Company received the final payment 80,156 4,219 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. On November 30, 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the years ended December 31, 2015 and 2014, the Company recognized $ 19,000 0 During the years ended December 31, 2015 and 2014, the Company recognized revenue related to sales of Stem Pearls skincare products of $ 425 2,219
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2015 and 2014. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. December 31, 2015 2014 Options 1,330,450 779,200 Warrants 1,066,930 412,422 Convertible notes 148,708 32,695 Total potentially dilutive shares 2,546,088 1,224,317
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTCQB Marketplace. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Advertising	Advertising Advertising costs are charged to operations as incurred. For the years ended December 31, 2015 and 2014, the Company incurred advertising costs of $ 23,467 15,280
Research and Development	Research and Development Research and development expenses are charged to operations as incurred. For the years ended December 31, 2015 and 2014, the Company incurred research and development expenses of $ 2,105,059 1,430,614
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
Convertible Instruments	Convertible Instruments The Company bifurcates When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. To allow entities additional time to implement systems, gather data and resolve implementation questions, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, in August 2015, to defer the effective date of ASU No. 2014-09 for one year, which is fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements or disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and annual and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this new standard will have on its financial statement disclosures. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 amends the existing guidance to require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related debt liability instead of as a deferred charge. ASU 2015-03 is effective on a retrospective basis for annual and interim reporting periods beginning after December 15, 2015; earlier adoption is permitted. Additionally, in August 2015 the FASB issued guidance expanding the April 2015 update (ASU No. 2015-15). It states that, given the absence of authoritative guidance within the update, the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset for revolving lines of credit and subsequently amortizing the deferred debt issuance costs ratably over the term of the arrangement, regardless of whether there are any outstanding borrowings on the line of credit. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years, with early adoption permitted for financial statements that have not been previously issued. Full retrospective application is required. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The FASB issued ASU 2015-17 as part of its ongoing Simplification Initiative, with the objective of reducing complexity in accounting standards. The amendments in ASU 2015-17 require entities that present a classified balance sheet to classify all deferred tax liabilities and assets as a noncurrent amount. This guidance does not change the offsetting requirements for deferred tax liabilities and assets, which results in the presentation of one amount on the balance sheet. Additionally, the amendments in ASU 2015-17 align the deferred income tax presentation with the requirements in International Accounting Standards (IAS) 1, Presentation of Financial Statements. The amendments in ASU 2015-17 are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2015 2014 Options 1,330,450 779,200 Warrants 1,066,930 412,422 Convertible notes 148,708 32,695 Total potentially dilutive shares 2,546,088 1,224,317

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and equipment include the following: December 31, 2015 2014 Office equipment $ 9,494 $ 8,466 Medical equipment 418,280 359,248 Furniture and fixtures 126,150 113,874 Computer software and equipment 85,118 66,458 Leasehold improvements 301,610 103,582 940,652 651,628 Less: accumulated depreciation (297,565) (157,772) Property and equipment, net $ 643,087 $ 493,856

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Intangible Assets [Abstract]
Schedule Of Intangible Assets By Major Class	Intangible assets consist of the following: Patents and Accumulated Trademarks Licenses Amortization Total Balance as of January 1, 2014 $ 3,676 $ 1,226,500 $ (122,631) $ 1,107,545 Amortization expense - - (69,813) (69,813) Balance as of December 31, 2014 3,676 1,226,500 (192,444) 1,037,732 Additions - 75,000 - 75,000 Amortization expense - - (73,991) (73,991) Balance as of December 31, 2015 $ 3,676 $ 1,301,500 $ (266,435) $ 1,038,741 Weighted average remaining amortization period at December 31, 2015 in years 5.0 13.9
Schedule Of Finite Lived Intangible Assets Amortization Expenses	Amortization of intangible assets consists of the following: Patents and Accumulated Trademarks Licenses Amortization Balance as of January 1, 2014 $ 1,104 $ 121,527 $ 122,631 Amortization expense 368 69,445 69,813 Balance as of December 31, 2014 1,472 190,972 192,444 Amortization expense 368 73,623 73,991 Balance as of December 31, 2015 $ 1,840 $ 264,595 $ 266,435

Accrued Expenses and Other Cu22

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: December 31, 2015 2014 Credit card payable $ 3,171 $ 4,739 Accrued payroll 1,010,633 679,277 Advances from related parties 87,030 - Accrued purchases of property and equipment - 174,801 Accrued research and development expenses 446,175 292,395 Accrued general and administrative expenses 456,182 315,294 Deferred rent 43,604 - Total $ 2,046,795 $ 1,466,506

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Payable [Abstract]
Notes Payable	A summary of the notes payable activity during the years ended December 31, 2015 and 2014 is presented below: Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, January 1, 2014 $ 4,000,000 $ 281,000 $ 1,473,500 $ (240,491) $ 5,514,009 Issuances 500,000 300,000 [1] - - 800,000 Exchanges for equity - (71,000) (203,000) - (274,000) Conversions to equity - (342,500) - - (342,500) Repayments (89,063) - (113,000) - (202,063) Recognition of debt discount - - - (347,170) [1] (347,170) Amortization of debt discount - - - 464,470 464,470 Recharacterization of accrued interest as principal - - 108,059 [3] - 108,059 Accretion of interest expense - 15,000 [2] - 9,934 [1] 24,934 Settlement of accreted interest - (7,500) [2] - - (7,500) Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 [4] $ 1,265,559 $ (113,257) $ 5,738,239 Issuances 150,000 735,000 [1] 478,018 [1] - 1,363,018 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (266,667) (877,873) - (5,555,477) Conversion to equity - (223,333) - - (223,333) Repayments - - (5,000) - (5,000) Recognition of debt discount - - - (469,557) [1] (469,557) Accretion of interest expense - - - 85,086 [1] 85,086 Amortization of debt discount - - - 339,443 339,443 Recharacterization of accrued interest as principal - - 44,379 [3] - 44,379 Outstanding, December 31, 2015 $ 150,000 $ 420,000 [4] $ 900,083 $ (158,285) $ 1,311,798 [1] During the years ended December 31, 2015 and 2014, notes with an aggregate principal amount of $ 538,018 30,000 450,015 25,000 88,003 5,000 75,000 65,000 [2] During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 June 10, 2014 90,000 105,000 15,000 7,500 January 8, 2014 30,000 [3] During the years ended December 31, 2015 and 2014, in connection with the extension of certain notes payable, an aggregate of $ 44,379 108,059 [4] As of December 31, 2015 and 2014, convertible notes with an aggregate principal balance of $ 420,000 175,000 197,500 83,333

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Tax effects of temporary differences that give rise to deferred tax assets	United States and foreign components of loss before income taxes were as follows: For The Years Ended December 31, 2015 2014 United States $ (7,767,924) $ (5,223,749) Foreign (155,556) (363,863) Loss before income taxes $ (7,923,480) $ (5,587,612) The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below: For The Years Ended December 31, 2015 2014 Deferred Tax Assets: Net operating loss carryforward $ 1,181,900 $ 4,820,500 Stock-based compensation 1,976,600 1,272,600 Accruals 231,100 240,700 Research & development tax credits 139,480 95,500 Other 2,100 2,100 Gross deferred tax assets 3,531,180 6,431,400 Deferred Tax Liabilities: Fixed assets (110,300) (93,200) Intangible assets (13,400) (8,100) Gross deferred tax liabilities (123,700) (101,300) Net deferred tax assets 3,407,480 6,330,100 Valuation allowance (3,407,480) (6,330,100) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ (2,922,620) $ (43,500)
Income tax provision (benefit)	The income tax provision (benefit) consists of the following: For The Years Ended December 31, 2015 2014 Federal: Current $ - $ - Deferred 2,614,976 38,921 State and local: Current - - Deferred 307,644 4,579 2,922,620 43,500 Change in valuation allowance (2,922,620) (43,500) Income tax provision (benefit) $ - $ -
Reconciliation of effective tax rate	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For The Years Ended December 31, 2015 2014 Tax benefit at federal statutory rate (34.0) % (34.0) % State income taxes, net of federal benefit (4.0) % (4.0) % Permanent differences 0.8 % 0.8 % Research & development tax credits (0.6) % (1.8) % Impact of Section 382 limit 76.0 % 41.2 % True-ups and other (0.6) % (1.4) % Change in valuation allowance (37.6) % (0.8) % Effective income tax rate 0.0 % 0.0 %

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For The Years Ended December 31, 2015 2014 Risk free interest rate 1.29% - 1.75 % 0.39% - 2.20 % Expected term (years) 5.00 1.96 - 5.00 Expected volatility 120% - 122 % 116% - 122 % Expected dividends 0.00 % 0.00 %
Summary of Warrant Activity	A summary of the warrant activity during the year ended December 31, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2015 412,422 $ 17.97 [1] Compensatory grants 65,000 8.85 Investor grants 664,981 9.14 Exercised (75,473) 3.50 [2] Forfeited - - Outstanding, December 31, 2015 1,066,930 $ 7.56 [1][3] 3.9 $ 150,651 Exercisable, December 31, 2015 1,031,930 $ 7.56 [3] 4.0 $ 150,651 [1] Excludes the impact of a warrant to purchase 35,000 30.00 [2] During the year ended December 31, 2015, warrants to purchase an aggregate of 75,473 4.00 15.00 3.50 [3] During the year ended December 31, 2015, warrants to purchase an aggregate of 527,308 5.00 20.00 4.00
Information Related to Stock Warrants	The following table presents information related to stock warrants at December 31, 2015: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 602,603 3.9 602,603 $5.00 - $5.99 138,500 4.9 138,500 $6.00 - $9.99 58,750 4.5 58,750 $10.00 - $14.99 74,732 4.3 74,732 $15.00 - $19.99 98,687 3.8 98,687 $20.00 - $80.00 58,658 1.7 58,658 Variable [1] 35,000 - - 1,066,930 4.0 1,031,930 [1] A warrant to purchase 35,000 30.00
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Years Ended December 31, 2015 2014 Risk free interest rate 1.33% - 2.24 % 1.13% - 2.66 % Expected term (years) 5.00 - 10.00 5.00 - 10.00 Expected volatility 120% - 123 % 132% - 135 % Expected dividends 0.00 % 0.00 %
Stock option expense	The following table presents information related to stock option expense: Weighted Average Remaining For The Years Ended Unrecognized at Amortization December 31, December 31, Period 2015 2014 2015 (Years) Consulting $ 595,446 $ 365,825 $ 755,416 2.3 Research and development 376,596 328,740 793,450 [1] 2.2 General and administrative 705,546 179,628 1,037,552 2.2 $ 1,677,588 $ 874,193 $ 2,586,418 2.2 [1] Includes $ 191,403
Summary of Option Activity	A summary of the option activity during the year ended December 31, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2015 779,200 $ 12.18 Granted 586,250 7.14 Exercised - - Forfeited (35,000) 6.34 Outstanding, December 31, 2015 1,330,450 $ 10.11 8.4 $ - Exercisable, December 31, 2015 679,577 $ 12.56 7.9 $ -
Information Related to Stock Options	The following table presents information related to stock options at December 31, 2015: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $4.40 - $6.99 368,750 8.3 131,250 $7.00 - $9.99 574,250 9.5 209,125 $10.00 - $19.99 202,000 7.4 160,752 $20.00 - $30.00 185,450 6.1 178,450 1,330,450 7.9 679,577
Common Stock Award Expense	The following table presents information related to compensatory common stock expense: For The Years Ended Unrecognized at December 31, December 31, 2015 2014 2015 Consulting $ 168,800 $ 276,500 $ - Research and development 8,847 24,337 - $ 177,647 $ 300,837 $ -

Business Organization and Nat26

Business Organization and Nature of Operations - Additional Information (Detail) - shares	Jul. 07, 2015	Dec. 31, 2015	Dec. 31, 2014
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio	the Company implemented a 1-for-20 reverse split
Changes in capital structure retroactive impact shares	200,000,000
Common stock, authorized	30,000,000	30,000,000	30,000,000

Going Concern and Management'27

Going Concern and Management's Plans - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 28, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency		$ 5,323,179
Stockholders deficiency		(3,908,463)	$ (6,888,393)	$ (6,685,069)
Net loss		(7,923,480)	(5,587,612)
Note principal and accrued interest converted to equity		5,555,477	274,000
Notes Payable		$ 1,311,798	$ 5,738,239	$ 5,514,009
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through equity financing	$ 1,831,270
Notes payable aggregate principal past due	514,518
Proceeds From Debt Financing	325,000
Subsequent Event | Research and Development Arrangement [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Repayments of Debt	103,500
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned	80,156
Notes Payable	163,000
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	310,000
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	$ 13,172

Calculation of Weighted Average

Calculation of Weighted Average Dilutive Common Shares (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	2,546,088	1,224,317
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	1,330,450	779,200
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	1,066,930	412,422
Convertible Notes
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	148,708	32,695

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended			12 Months Ended
	Mar. 31, 2016	Mar. 24, 2014	Mar. 19, 2014	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Advertising Expense				$ 23,467	$ 15,280
Research and Development Expense				2,105,059	1,430,614
Deferred Revenue, Current				0	164,349
Revenues				628,915	415,996
Accounts Receivable, Net, Current				93,375	0
Sublicense Agreement
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized				19,000	0
Research and Development Agreements One Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms		Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all three of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable.	Payment terms were (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method).
Revenues				250,000
Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current		$ 250,000
Accounts Receivable, Net, Current				84,375
Proceeds from Research and Development Agreement				688,892
Sales Discounts, Services				1,733
Revenue, Net, Total				$ 773,267
Research and development agreements | Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned	$ 80,156
Accretion of Discount	$ 4,219
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life				3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life				5 years
Trademarks
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life				10 years
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenues				$ 425	2,219
Licenses
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life				17 years 8 months 12 days
Japanese Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned				$ 134,281	115,719
U.S. Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned				$ 475,209	$ 298,058

Property and Equipment, net (De

Property and Equipment, net (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Office equipment	$ 9,494	$ 8,466
Medical equipment	418,280	359,248
Furniture and fixtures	126,150	113,874
Computer software and equipment	85,118	66,458
Leasehold improvements	301,610	103,582
Property, Plant and Equipment, Gross	940,652	651,628
Less: accumulated depreciation	(297,565)	(157,772)
Property and equipment, net	$ 643,087	$ 493,856

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 139,793	$ 26,872

Intangible Assets (Detail)

Intangible Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$ 1,037,732	$ 1,107,545
Additions	75,000
Amortization expense	(73,991)	(69,813)
Ending Balance	1,038,741	1,037,732
Patents and Trademarks
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	3,676	3,676
Additions	0
Amortization expense	0	0
Ending Balance	$ 3,676	3,676
Weighted Average Amortization Period	5 years
Licensing Agreements
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$ 1,226,500	1,226,500
Additions	75,000
Amortization expense	0	0
Ending Balance	$ 1,301,500	1,226,500
Weighted Average Amortization Period	13 years 10 months 24 days
Accumulated Amortization
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$ (192,444)	(122,631)
Additions	0
Amortization expense	(73,991)	(69,813)
Ending Balance	$ (266,435)	$ (192,444)

Amortization of Intangible Asse

Amortization of Intangible Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Patents and Trademarks
Accumulated Amortization [Line Items]
Beginning Balance	$ 1,472	$ 1,104
Amortization expense	368	368
Ending Balance	1,840	1,472
Licensing Agreements
Accumulated Amortization [Line Items]
Beginning Balance	190,972	121,527
Amortization expense	73,623	69,445
Ending Balance	264,595	190,972
Accumulated Amortization
Accumulated Amortization [Line Items]
Beginning Balance	192,444	122,631
Amortization expense	73,991	69,813
Ending Balance	$ 266,435	$ 192,444

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($)	Mar. 05, 2015	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization		$ 75,000
Milestones payment	$ 75,000
Maximum
Finite-Lived Intangible Assets [Line Items]
Milestones payment	475,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Milestones payment	$ 225,000

Accrued Expenses and Other Cu35

Accrued Expenses and Other Current Liabilities (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 3,171	$ 4,739
Accrued payroll	1,010,633	679,277
Advances from related parties	87,030	0
Accrued purchases of property and equipment	0	174,801
Accrued research and development expenses	446,175	292,395
Accrued general and administrative expenses	456,182	315,294
Deferred rent	43,604	0
Total	$ 2,046,795	$ 1,466,506

Accrued Expenses and Other Cu36

Accrued Expenses and Other Current Liabilities - Additional Information (Detail) - USD ($)	Dec. 07, 2015	Oct. 09, 2015	Dec. 31, 2015	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer		$ 150,000	$ 564,105	$ 58,054
Repayment of advances from officer			387,075	83,044
Proceeds from Convertible Debt			65,000
Debt Instrument, Annual Principal Payment			$ 75,000
Debt Instrument, Maturity Date	Mar. 9, 2016		Oct. 30, 2015
Debt Conversion, Original Debt, Amount			$ 25,000
Debt Conversion, Converted Instrument, Shares Issued			6,250
Debt Conversion, Converted Instrument, Amount			$ 223,333	342,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	239,182		6,250
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4	$ 15	$ 4
Warrants and Rights Outstanding			$ 11,063
Warrants Expiration Period			5 years
Loss on extinguishment of notes payable, net			$ (35,677)	(49,094)
Common Stock and Warrant [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Loss on extinguishment of notes payable, net			126
Common Stock [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Debt Conversion, Converted Instrument, Amount			14,063
Non-Interest Bearing Advance [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer			564,105	58,054
Repayment of advances from officer			$ 387,075	$ 83,044

Notes Payable (Detail)

Notes Payable (Detail) - USD ($)		12 Months Ended
		Dec. 31, 2015		Dec. 31, 2014
Debt Instrument [Line Items]
Outstanding		$ 5,738,239		$ 5,514,009
Issuance		1,363,018		800,000
Indebtedness satisfied via settlement		(5,000)
Exchanges to equity		(5,555,477)		(274,000)
Conversions to equity		(223,333)		(342,500)
Repayments		(5,000)		(202,063)
Recognition of debt discount		(469,557)		(347,170)
Accretion of interest expense		85,086		24,934
Amortization of debt discount		339,443		464,470
Recharacterization of accrued interest as principal		44,379		108,059
Settlement of accreted interest				(7,500)
Outstanding		1,311,798		5,738,239
Debt Discount
Debt Instrument [Line Items]
Outstanding		(113,257)		(240,491)
Issuance		0		0
Indebtedness satisfied via settlement		0
Exchanges to equity		0		0
Conversions to equity		0		0
Repayments		0		0
Recognition of debt discount	[1]	(469,557)		(347,170)
Accretion of interest expense	[1]	85,086		9,934
Amortization of debt discount		339,443		464,470
Recharacterization of accrued interest as principal		0		0
Settlement of accreted interest				0
Outstanding		(158,285)		(113,257)
Bermuda Lender
Debt Instrument [Line Items]
Outstanding		4,410,937		4,000,000
Issuance		150,000		500,000
Indebtedness satisfied via settlement		0
Exchanges to equity		(4,410,937)		0
Conversions to equity		0		0
Repayments		0		(89,063)
Recognition of debt discount		0		0
Accretion of interest expense		0		0
Amortization of debt discount		0		0
Recharacterization of accrued interest as principal		0		0
Settlement of accreted interest				0
Outstanding		150,000		4,410,937
Convertible Notes
Debt Instrument [Line Items]
Outstanding		175,000	[2]	281,000
Issuance	[1]	735,000		300,000
Indebtedness satisfied via settlement		0
Exchanges to equity		(266,667)		(71,000)
Conversions to equity		(223,333)		(342,500)
Repayments		0		0
Recognition of debt discount		0		0
Accretion of interest expense		0		15,000	[3]
Amortization of debt discount		0		0
Recharacterization of accrued interest as principal		0		0
Settlement of accreted interest	[3]			(7,500)
Outstanding	[2]	420,000		175,000
Other Notes
Debt Instrument [Line Items]
Outstanding		1,265,559		1,473,500
Issuance		478,018	[1]	0
Indebtedness satisfied via settlement		(5,000)
Exchanges to equity		(877,873)		(203,000)
Conversions to equity		0		0
Repayments		(5,000)		(113,000)
Recognition of debt discount		0		0
Accretion of interest expense		0		0
Amortization of debt discount		0		0
Recharacterization of accrued interest as principal	[4]	44,379		108,059
Settlement of accreted interest				0
Outstanding		$ 900,083		$ 1,265,559
[1]	During the years ended December 31, 2015 and 2014, notes with an aggregate principal amount of $538,018 and $30,000, respectively, bear no interest and were issued for cash consideration of $450,015 and $25,000, respectively. The difference between the principal amount of the notes and the cash received of $88,003 and $5,000, respectively, was recorded as debt discount and is being accreted to interest expense over the term of the notes. During the year ended December 31, 2015 the Company issued a note payable in the principal amount of $75,000 for a short term advance from a related party in the amount of $65,000.
[2]	As of December 31, 2015 and 2014, convertible notes with an aggregate principal balance of $420,000 and $175,000, respectively, became convertible into shares of common stock at the election of the Company near maturity. Of such aggregate principal balance the holder has the right to accelerate the conversion of up to $197,500 and $83,333, respectively, of principal into shares of common stock.
[3]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
[4]	During the years ended December 31, 2015 and 2014, in connection with the extension of certain notes payable, an aggregate of $44,379 and $108,059, respectively, of accrued interest was added to the aggregate principal balance of the notes.

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	Dec. 07, 2015	Oct. 09, 2015	May. 11, 2015	Aug. 13, 2014	Jul. 15, 2014	May. 27, 2015	Dec. 02, 2014	Mar. 31, 2015	May. 02, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	May. 08, 2014
Debt Instrument [Line Items]
Extended maturity date of the note	Mar. 9, 2016									Oct. 30, 2015
Rate of interest		10.00%
Debt instrument, face amount		$ 150,000
Warrants to purchase common stock										259,464	116,535
Loss on extinguishment of note payables, net										$ 35,677	$ 49,094
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	239,182									6,250
Debt Instrument Unamortized Discount	$ 98,739
Debt Instrument Annual Principal Payment										$ 75,000
Debt Instrument, Convertible, Beneficial Conversion Feature										87,788	92,370
Debt Conversion, Original Debt, Amount										$ 25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4	$ 15								$ 4
Amortization Of Debt Discount (Premium)										$ 339,443	464,470
Proceeds from Convertible Debt										65,000
Gains (Losses) On Extinguishment Of Debt										$ (35,677)	(49,094)
Class Of Warrant Or Rights Expiration Date								Dec. 31, 2015
Debt Conversion, Converted Instrument, Shares Issued										6,250
Warrants and Rights Outstanding										$ 11,063
Debt Instrument, Annual Principal Payment										75,000
Proceeds From Related Party Debt		$ 150,000								564,105	58,054
Repayments of Other Debt										5,000	113,000
Warrant Modification Charge										229,288	50,035
Notes Payable, Noncurrent, Total										302,001	50,000
Debt Instrument Unamortized Debt Discount Noncurrent Portion										7,999	0
Other Accrued Liabilities, Noncurrent										$ 11,011	$ 5,195
Common Stock [Member]
Debt Instrument [Line Items]
Stock issued (in shares)										395,425	433,600
Debt Instrument, Convertible, Beneficial Conversion Feature										$ 0	$ 0
Warrant Modification Charge										0	0
Notes Payable
Debt Instrument [Line Items]
Debt instrument, face amount										538,018	30,000
Debt Instrument Annual Principal Payment										75,000
Amortization Of Debt Discount (Premium)										88,003	5,000
Proceeds from Convertible Debt										450,015	25,000
Debt Instrument, Annual Principal Payment										75,000
Proceeds From Related Party Debt										$ 65,000
Other Notes Payable
Debt Instrument [Line Items]
Rate of interest										15.00%
Loss on extinguishment of note payables, net										$ 21,537
Common stock aggregate grant date fair value										982,112	29,800
Debt Conversion, Original Debt, Amount										$ 877,873
Conversion of Stock, Shares Issued										188,632
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount										$ 82,701
Warrants Issued During Period, Number of Warrants1										111,358
Gains (Losses) On Extinguishment Of Debt										$ (21,537)
First Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal							$ 41,667
Second Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal							41,667
Third Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal							$ 41,666
Other Notes Payable One
Debt Instrument [Line Items]
Warrants to purchase common stock										35,215
Common stock aggregate grant date fair value										$ 88,875
Debt Conversion, Original Debt, Amount										$ 735,081
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 4
Warrants Issued During Period, Number of Warrants1										37,500
Notes Payable One
Debt Instrument [Line Items]
Debt instrument, face amount											7,500
Debt Instrument Periodic Payment Interest											15,000
Debt Instrument, Increase, Accrued Interest											105,000	$ 90,000
Debt Conversion, Original Debt, Amount											$ 30,000
Debt Instrument, Maturity Date Range, Start											Jan. 8, 2014
Debt Instrument, Maturity Date Range, End											Jun. 10, 2014
Notes Payable Two
Debt Instrument [Line Items]
Accrued loan interest										$ 44,379	$ 108,059
Scenario, Previously Reported [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock											9,500
Minimum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price											$ 3.80
Minimum | Other Notes Payable
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 4	10
Minimum | Other Notes Payable One
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										10
Maximum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price											4.40
Maximum | Other Notes Payable
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										15	$ 15
Maximum | Other Notes Payable One
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 4
In exchange of notes payable
Debt Instrument [Line Items]
Loss on extinguishment of note payables, net										$ 8,813	$ 50,323
Common stock aggregate grant date fair value										288,060	$ 268,997
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											5,000
Debt Conversion, Original Debt, Amount											$ 117,500
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 15
Amortization Of Debt Discount (Premium)										$ 0	$ 0
Conversion of Stock, Shares Issued										92,875	42,735
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount										$ 12,580	$ 15,672
Warrants Issued During Period, Number of Warrants1										39,092	5,000
Gains (Losses) On Extinguishment Of Debt										$ (8,813)	$ (50,323)
Debt Conversion, Converted Instrument, Shares Issued											12,339
Accrued Interest Converted Into Stock											$ 3,646
Warrants and Rights Outstanding						$ 3,733,645					74,029
In exchange of notes payable | Lenders [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount											$ 203,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 15
Convertible Notes
Debt Instrument [Line Items]
Rate of interest							10.00%			10.00%
Loss on extinguishment of note payables, net											$ 1,231
Debt instrument conversion period description										(a) a range of 55% to 65% of the fair value of the Company's common stock or (b) $2.00 or $3.00 per share depending on the note.In the event that the Company elects to convert a portion of the $272,500 of principal outstanding under the notes into common stock, the holder will have the right to convert the remaining principal into shares of common stock at the same conversion price. In connection with the issuance of the convertible notes, the Company issued five-year, immediately vested warrants to purchase an aggregate of 30,885 shares of common stock at exercise prices ranging from $5.00 to $10.00 per share.	(a) 60% of the fair value of the Companys stock or (b) $1.00 per share. In the event that the Company elects to effect a conversion of a specific note during the five day period following the conversion, the holder of that note shall have the right to convert the remaining outstanding principal amount of the convertible note, together with accrued and unpaid interest thereon, into shares of the Companys common stock at a conversion price equal to the conversion price in the Company-effected conversion
Debt Instrument Unamortized Discount										$ 90,018
Debt Instrument, Frequency of Periodic Payment									The convertible notes were initially payable 3-12 months from the date of issuance
Debt Instrument, Convertible, Beneficial Conversion Feature									$ 145,000
Debt Conversion, Original Debt, Amount										223,333	$ 71,000
Amortization Of Debt Discount (Premium)										$ 0	$ 0
Conversion of Stock, Shares Issued										53,595	29,102
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount										$ 15,175	$ 4,260
Proceeds from Convertible Debt									$ 175,000
Gains (Losses) On Extinguishment Of Debt											$ (1,231)
Debt Conversion Original Debt Shares Issued											60,138
Original Debt Accrued Interest Converted Into Stock											$ 13,565
Convertible Notes | Lenders [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount										266,667	225,000
Convertible Notes | Other Notes Payable One
Debt Instrument [Line Items]
Rate of interest									12.00%
Debt instrument, face amount									$ 175,000	735,000
Debt Instrument Annual Principal Payment									30,000
Debt Instrument issued for consideration									25,000
Debt Instrument Periodic Payment Interest									5,000	10,000
Debt Instrument, Periodic Payment, Principal									145,000
Proceeds from Convertible Debt									170,000	725,000
Debt Instrument, Annual Principal Payment									$ 30,000
Convertible Notes | Other Notes Payable Two
Debt Instrument [Line Items]
Debt instrument, face amount										478,018
Debt Instrument Periodic Payment Interest										78,003
Proceeds from Convertible Debt										400,015
Convertible Notes | Notes Payable Three
Debt Instrument [Line Items]
Debt instrument, face amount										420,000	175,000
Proceeds from Convertible Debt										$ 197,500	$ 83,333
Convertible Notes | Minimum
Debt Instrument [Line Items]
Rate of interest										1.00%
Percentage of royalty payments										2.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 3
Debt Instrument, Convertible, Conversion Price											$ 2.80
Convertible Notes | Maximum
Debt Instrument [Line Items]
Rate of interest										12.00%
Percentage of royalty payments										4.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 5.16
Debt Instrument, Convertible, Conversion Price											$ 5.60
Bermuda Lender
Debt Instrument [Line Items]
Aggregate principal amount													$ 500,000
Debt instrument, face amount			$ 500,000	$ 4,000,000		$ 4,410,937
Warrants to purchase common stock										12,500
Stock issued (in shares)				27,500						50,000	22,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						186,682
Debt instrument, interest rate, effective percentage													15.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 15				$ 15
Debt Instrument, Maturity Date Range, Start			May 7, 2015	Jul. 31, 2014							Dec. 31, 2014
Debt Instrument, Maturity Date Range, End			Jun. 30, 2015	Dec. 31, 2014							Jun. 30, 2015
Amortization Of Debt Discount (Premium)				$ 121,000
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable						746,730
Cash Proceeds From Research Agreements					$ 89,063
Debt Default, Short-term Debt, Amount			$ 316,297
Interest Payable						$ 69,436
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value						672,056				$ 40,000
Warrant Modification Charge						$ 80,000
Bermuda Lender | Warrants
Debt Instrument [Line Items]
Loss on extinguishment of note payables, net										(5,327)
Gains (Losses) On Extinguishment Of Debt										$ 5,327
Bermuda Lender | Common Stock [Member]
Debt Instrument [Line Items]
Amortization Of Debt Discount (Premium)											$ 99,000
Class of Warrant or Right, Outstanding										40,000
Bermuda Lender | Cayman
Debt Instrument [Line Items]
Aggregate principal amount			$ 410,938
Bermuda Lender | Notes Payable | Cayman
Debt Instrument [Line Items]
Aggregate principal amount										$ 10,000
Bermuda Lender | Other Notes Payable | Cayman
Debt Instrument [Line Items]
Debt instrument, face amount										$ 10,234

Loss before income taxes (Detai

Loss before income taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Before Income Tax Domestic And Foreign [Line Items]
United States	$ (7,767,924)	$ (5,223,749)
Foreign	(155,556)	(363,863)
Loss before income taxes	$ (7,923,480)	$ (5,587,612)

Deferred Tax Assets (Detail)

Deferred Tax Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets:
Net operating loss carryforward	$ 1,181,900	$ 4,820,500
Stock-based compensation	1,976,600	1,272,600
Accruals	231,100	240,700
Research & development tax credits	139,480	95,500
Other	2,100	2,100
Gross deferred tax assets	3,531,180	6,431,400
Deferred Tax Liabilities:
Fixed assets	(110,300)	(93,200)
Intangible assets	(13,400)	(8,100)
Gross deferred tax liabilities	(123,700)	(101,300)
Net deferred tax assets	3,407,480	6,330,100
Valuation allowance	(3,407,480)	(6,330,100)
Deferred tax asset, net of valuation allowance	0	0
Changes in valuation allowance	$ (2,922,620)	$ (43,500)

Income Tax Provision (benefit)

Income Tax Provision (benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Federal:
Current	$ 0	$ 0
Deferred	2,614,976	38,921
State and local:
Current	0	0
Deferred	307,644	4,579
Income tax provision (benefit) before change in valuation allowance	2,922,620	43,500
Change in valuation allowance	(2,922,620)	(43,500)
Income tax provision (benefit)	$ 0	$ 0

Statutory Federal Income Tax Ra

Statutory Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Tax benefit at federal statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(4.00%)	(4.00%)
Permanent differences	0.80%	0.80%
Research & development tax credits	(0.60%)	(1.80%)
Impact of Section 382 limit	76.00%	41.20%
True-ups and other	(0.60%)	(1.40%)
Change in valuation allowance	(37.60%)	(0.80%)
Effective income tax rate	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Federal and state net operating losses	$ 3,100,000	$ 12,700,000
Operating Loss Carry forwards Expiration Period	The net operating loss carry forwards, if not utilized, will expire from 2029 to 2035 for federal purposes
Percentage of ownership changes	50.00%
Description for Section 382 limitation One	approximately $15,500,000 and $5,700,000, respectively,of federal NOLs not being realizable
Description for Section 382 limitation two	the reversal of approximately $5,900,000 and $2,200,000, respectively,of net operating loss deferred tax assets

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

Aug. 13, 2015USD ($)$ / sharesshares

Mar. 09, 2015USD ($)

Feb. 09, 2015USD ($)$ / sharesshares

Oct. 08, 2014USD ($)$ / sharesshares

Oct. 07, 2014USD ($)

May. 09, 2014USD ($)

Mar. 14, 2014USD ($)$ / sharesshares

Mar. 12, 2014USD ($)$ / sharesshares

Feb. 04, 2014USD ($)

Jan. 11, 2011

Mar. 28, 2016shares

Oct. 31, 2014USD ($)

Oct. 23, 2014USD ($)

Aug. 27, 2014USD ($)shares

Aug. 25, 2014USD ($)a$ / sharesshares

Jul. 23, 2014shares

Jun. 27, 2014USD ($)$ / sharesshares

Feb. 20, 2014USD ($)$ / sharesshares

Nov. 30, 2013

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)shares

Dec. 07, 2015$ / sharesshares

Oct. 09, 2015$ / shares

Commitments and Contingencies Disclosure [Line Items]

Lease Expiration Date

Jul. 31, 2014

Jan. 31, 2014

Lease Rent Second Year

$ 6,234

Lease Rent Third Year

6,422

Research and Development Expense

2,105,059

$ 1,430,614

Accounts Payable and Accrued Liabilities, Total

$ 112,000

43,000

Stock issued during period, value, issued for services

$ 2,420

Stock-based compensation, stock option granted | shares

586,250

Common stock exercise price | $ / shares

$ 7.14

Number of shares called by warrants | shares

6,250

239,182

Initial year Salary

$ 25,000

Percentage Of Increase Salary

28.00%

Employee-related Liabilities

$ 797,576

574,278

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 4

$ 4

$ 15

Monthly Payments for Leasing

$ 962

Leasehold Improvements, Gross

$ 301,610

103,582

Rent Expense

141,131

20,380

Professional Fees

$ 1,394,037

1,310,121

Monthly Payments under Consulting Agreements

$ 15,000

Warrants Issued During Period, Number of Warrants | shares

15,000

125,000

Share Based Compensation

$ 1,954,736

1,360,296

Security Deposit

45,900

45,900

Operating Expenses

$ 7,537,773

$ 5,124,668

Warrants Issue One [Member]

Commitments and Contingencies Disclosure [Line Items]

Warrants Issued During Period, Number of Warrants | shares

5,000

Warrants Issued During Period, Exercise Price at Issuance Date | $ / shares

$ 10.60

Warrants Issue Two [Member]

Commitments and Contingencies Disclosure [Line Items]

Warrants Issued During Period, Number of Warrants | shares

14,000

Warrants Issued During Period, Exercise Price at Issuance Date | $ / shares

$ 10.60

Warrants Issue Three [Member]

Commitments and Contingencies Disclosure [Line Items]

Warrants Issued During Period, Number of Warrants | shares

30

Warrants Issued During Period, Exercise Price at Issuance Date | $ / shares

$ 1,000

Chief Medical Advisor [Member]

Commitments and Contingencies Disclosure [Line Items]

Stock-based compensation, stock option granted | shares

15,000

Common stock exercise price | $ / shares

$ 13

Monthly Payments under Consulting Agreements

15,000

$ 10,000

Monthly Escalating Payments under Consulting Agreements

$ 20,000

20,000

Warrant [Member]

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$ 23,270

Allocated Share-Based Compensation Expense

$ 30,096

Common Stock [Member]

Commitments and Contingencies Disclosure [Line Items]

Stock Issued During Period, Shares, Other | shares

29,773

Stock Issued During Period, Shares, New Issues | shares

395,425

433,600

Legal Settlement Agreement [Member]

Commitments and Contingencies Disclosure [Line Items]

Stock Issued During Period, Shares, New Issues | shares

4,230

Class of Warrant or Right, Outstanding | shares

30,000

Proceeds from Issuance of Warrants

$ 152,000

Legal Settlement Agreement [Member] | Minimum

Commitments and Contingencies Disclosure [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 7.60

Legal Settlement Agreement [Member] | Maximum

Commitments and Contingencies Disclosure [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 12

Chief Executive Officer

Commitments and Contingencies Disclosure [Line Items]

Deferred Compensation Arrangement with Individual, Description

the CEO is entitled to receive a salary of $400,000 per annum and, effective January 1, 2015, the CEOs annual car allowance was reduced to $14,400 from $28,800. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Companys Compensation Committee, are satisfied

Pursuant to the amendment, the CEO would still be entitled to an annual bonus equal to 50% of his annual salary and an annual car allowance of $28,800

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

$ 100,000

Labor and Related Expense, Total

$ 28,800

Operating Expenses

$ 723,800

$ 614,400

Consultant

Commitments and Contingencies Disclosure [Line Items]

Grant date value

49,800

33,000

Stock issued during period shares for services | shares

1,500

Consulting expense

$ 59,000

$ 10,000

Number of shares immediately vest on date of grants | shares

10,500

7,500

Initial year Salary

$ 15,000

Second year salary

$ 10,000

Non Employee Director Awards

Commitments and Contingencies Disclosure [Line Items]

Accounts Payable and Accrued Liabilities, Total

$ 200,000

$ 105,000

Board of Directors

Commitments and Contingencies Disclosure [Line Items]

Salaries, Wages and Officers Compensation, Total

$ 80,000

Compensation Paid To Directors Aggregate Amount

30,000

Compensation Paid To Directors Installment Amount

50,000

Share Based Compensation

$ 96,250

Employees and Directors

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$ 15,000

$ 15,000

Stock issued during period, value, issued for services

$ 5,000

Stock-based compensation, stock option granted | shares

1,725

1,840

Monthly Payments under Consulting Agreements

$ 10,000

Division President

Commitments and Contingencies Disclosure [Line Items]

Stock-based compensation, stock option granted | shares

25,000

Common stock exercise price | $ / shares

$ 9.20

Severance Costs

$ 150,000

Share Based Compensation Arrangement By Share Based Payment Award Options Grant Intrinsic Value

$ 200,400

Chief medical Officer, Spine Medicine [Member]

Commitments and Contingencies Disclosure [Line Items]

Stock-based compensation, stock option granted | shares

25,000

Common stock exercise price | $ / shares

$ 6.40

Salaries, Wages and Officers Compensation, Total

$ 180,000

$ 115,000

Business Advisory Services

Commitments and Contingencies Disclosure [Line Items]

Stock-based compensation, stock option granted | shares

15,000

Marketing Consulting Services

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock | shares

12,500

Exercise price of warrant | $ / shares

$ 20

Marketing Consulting Services | Consultant

Commitments and Contingencies Disclosure [Line Items]

Contractual Obligation

$ 65,000

Consulting Expense In Shares | shares

25,000

Business Advisory Services Immediately Vesting

Commitments and Contingencies Disclosure [Line Items]

Consulting expense

$ 75,000

Consulting Services

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$ 124,200

$ 67,830

August 16, 2015

Commitments and Contingencies Disclosure [Line Items]

Number of shares vest on first anniversary of date of grant | shares

7,500

August 16, 2016

Commitments and Contingencies Disclosure [Line Items]

Number of shares vest on second anniversary of date of grant | shares

7,500

Effective From October 1, 2014 [Member] | Chief Executive Officer

Commitments and Contingencies Disclosure [Line Items]

Salaries, Wages and Officers Compensation, Total

600,000

Salary Reduced

$ 450,000

Effective From January 1, 2015 [Member] | Chief Executive Officer

Commitments and Contingencies Disclosure [Line Items]

Salaries, Wages and Officers Compensation, Total

450,000

Salary Reduced

400,000

Research and Development Arrangement

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

103,000

264,000

Professional Fees

$ 208,335

323,336

Gain On Settlement Related To Agreement

166,668

Research and Development Arrangement | Minimum

Commitments and Contingencies Disclosure [Line Items]

Fees payable for services per month

20,000

Research and Development Arrangement | Maximum

Commitments and Contingencies Disclosure [Line Items]

Fees payable for services per month

$ 41,667

Marketing Consulting Services Agreement

Commitments and Contingencies Disclosure [Line Items]

Consulting expense

0

82,500

Marketing Consulting Services Agreement | Warrant [Member]

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$ 37,500

Marketing Consulting Services Agreement | Common Stock [Member]

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$ 110,000

Business Advisory Services

Commitments and Contingencies Disclosure [Line Items]

Fair Value Adjustment of Warrants

$ 74,923

Business Advisory Services | Extension 1

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock | shares

10,000

12,500

Exercise price of warrant | $ / shares

$ 20

Grant date value

$ 37,500

Additional Monthly Fee For Services Rendered

$ 15,000

$ 16,667

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 12

Business Advisory Services | Extension 2

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock | shares

10,000

5,000

Exercise price of warrant | $ / shares

$ 10

Grant date value

$ 17,000

Additional Monthly Fee For Services Rendered

15,000

Consulting expense

180,000

150,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 10

Chief Executive Officer Employment Agreements

Commitments and Contingencies Disclosure [Line Items]

Severance Costs

125,000

175,000

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

$ 300,000

Scientific Advisory Services

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$ 5,860

$ 81,000

Total options granted | shares

1,250

15,000

Stock options granted exercise price per share | $ / shares

$ 10

$ 5.70

Number of shares immediately vest on date of grants | shares

625

Number of shares vest on first anniversary of date of grant | shares

625

Monthly Payments under Consulting Agreements

$ 10,000

Scientific Advisory Services | Advisors

Commitments and Contingencies Disclosure [Line Items]

Total options granted | shares

250

Scientific Advisory Services | Board of Directors

Commitments and Contingencies Disclosure [Line Items]

Salaries, Wages and Officers Compensation, Total

120,000

$ 120,000

Melville Lease

Commitments and Contingencies Disclosure [Line Items]

Number of shares called by warrants | shares

7,105

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 10

Land Subject to Ground Leases | a

6,800

Land Lease Term

63 months

Stock Issued During Period, Shares, Other | shares

14,210

Description Of Leasing Arrangement Consideration

(i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease.

Stock Issued During Period, Shares, New Issues | shares

71,050

Leasehold Improvements, Gross

$ 60,000

Prepaid Rent

$ 11,050

Security Deposit

$ 45,900

Loss Contingency, Allegations

The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.

Melville Lease | Minimum

Commitments and Contingencies Disclosure [Line Items]

Accrued Rent

$ 132,600

Melville Lease | Maximum

Commitments and Contingencies Disclosure [Line Items]

Accrued Rent

$ 149,260

Black-Scholes Option Pricing Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) - Warrants	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years
Expected dividends	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.29%	0.39%
Expected term (years)		1 year 11 months 16 days
Expected volatility	120.00%	116.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.75%	2.20%
Expected term (years)		5 years
Expected volatility	122.00%	122.00%

Summary of Warrant Activity (De

Summary of Warrant Activity (Detail) - Warrants	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Number of Warrants
Beginning Balance | shares	412,422
Compensatory grants | shares	65,000
Investor grants | shares	664,981
Exercised | shares	(75,473)
Forfeited | shares	0
Ending Balance | shares	1,066,930
Exercisable | shares	1,031,930
Weighted Average Exercise Price
Beginning Balance | $ / shares	$ 17.97
Compensatory grants | $ / shares	8.85
Investor grants | $ / shares	9.14
Exercised | $ / shares	3.50	[1]
Forfeited | $ / shares	0
Ending Balance | $ / shares	7.56	[2],[3]
Exercisable | $ / shares	$ 7.56	[2]
Weighted Average Remaining Life In Years
Outstanding	3 years 10 months 24 days
Exercisable	4 years
Aggregate Intrinsic Value
Outstanding | $	$ 150,651
Exercisable | $	$ 150,651
[1]	During the year ended December 31, 2015, warrants to purchase an aggregate of 75,473 shares of common stock, with original exercise prices ranging from $4.00 to $15.00 per share, had their exercise prices reduced to $3.50 per share. See Note 10 – Stockholders’ Deficiency – Warrant Exercises for additional details.
[2]	During the year ended December 31, 2015, warrants to purchase an aggregate of 527,308 shares of common stock, with original exercise prices ranging from $5.00 to $20.00 per share, had their exercise prices reduced to a weighted average exercise price of $4.00 per share.
[3]	Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur prior to December 31, 2015.

Summarized Information Related

Summarized Information Related to Stock Warrants (Detail)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,066,930
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years
Warrants Exercisable, Exercisable Number of Warrants	1,031,930
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	602,603
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	602,603
Exercise Price 1 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price 1 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	138,500
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	138,500
Exercise Price 2 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price 2 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	58,750
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	58,750
Exercise Price 3 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 9.99
Exercise Price 3 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	74,732
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	74,732
Exercise Price 4 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 14.99
Exercise Price 4 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	98,687
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	98,687
Exercise Price 5 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price 5 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 15
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	58,658
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	58,658
Exercise Price 6 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 80
Exercise Price 6 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 20
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	35,000	[1]
Warrants Exercisable, Weighted Average Remaining Life In Years	0 years	[1]
Warrants Exercisable, Exercisable Number of Warrants	0	[1]
[1]	A warrant to purchase 35,000 shares of common stock has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur prior to December 31, 2015.

Black-Scholes Option Pricing 48

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) - Stock Options	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.33%	1.13%
Expected term (years)	5 years	5 years
Expected volatility	120.00%	132.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.24%	2.66%
Expected term (years)	10 years	10 years
Expected volatility	123.00%	135.00%

Information Related to Stock Op

Information Related to Stock Option Expense (Detail) - Stock Options - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		$ 1,677,588	$ 874,193
Unrecognized expense		$ 2,586,418
Weighted Average Remaining Amortization Period (Years)		2 years 2 months 12 days
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		$ 595,446	365,825
Unrecognized expense		$ 755,416
Weighted Average Remaining Amortization Period (Years)		2 years 3 months 18 days
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		$ 376,596	328,740
Unrecognized expense	[1]	$ 793,450
Weighted Average Remaining Amortization Period (Years)		2 years 2 months 12 days
General and administrative
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		$ 705,546	$ 179,628
Unrecognized expense		$ 1,037,552
Weighted Average Remaining Amortization Period (Years)		2 years 2 months 12 days
[1]	Includes $191,403 of expense that is subject to non-employee mark-to-market adjustments.

Summary of Stock Option Activit

Summary of Stock Option Activity (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Number of Options
Outstanding | shares	779,200
Granted | shares	586,250
Exercised | shares	0
Forfeited | shares	(35,000)
Outstanding | shares	1,330,450
Exercisable | shares	679,577
Weighted Average Exercise Price
Outstanding | $ / shares	$ 12.18
Granted | $ / shares	7.14
Exercised | $ / shares	0
Forfeited | $ / shares	6.34
Outstanding | $ / shares	10.11
Exercisable | $ / shares	$ 12.56
Weighted Average Remaining Life In Years
Outstanding	8 years 4 months 24 days
Exercisable	7 years 10 months 24 days
Aggregate Intrinsic Value
Outstanding | $	$ 0
Exercisable | $	$ 0

Information Related to Stock 51

Information Related to Stock Options (Detail)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	1,330,450
Options Exercisable, Weighted Average Remaining Life In Years	7 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	679,577
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	368,750
Options Exercisable, Weighted Average Remaining Life In Years	8 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	131,250
Exercise Price 1 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6.99
Exercise Price 1 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4.40
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	574,250
Options Exercisable, Weighted Average Remaining Life In Years	9 years 6 months
Options Exercisable, Exercisable Number of Options	209,125
Exercise Price 2 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 9.99
Exercise Price 2 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 7
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	202,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	160,752
Exercise Price 3 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price 3 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	185,450
Options Exercisable, Weighted Average Remaining Life In Years	6 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	178,450
Exercise Price 4 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 30
Exercise Price 4 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 20

Information Related to Common S

Information Related to Common Stock Award Expense (Detail) - Common Stock Award - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 177,647	$ 300,837
Unrecognized expense	0
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	168,800	276,500
Unrecognized expense	0
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	8,847	$ 24,337
Unrecognized expense	$ 0

Stockholders' Deficiency - Addi

Stockholders' Deficiency - Additional Information (Detail) - USD ($)	Jul. 07, 2015	Oct. 07, 2014	Aug. 13, 2014	Mar. 28, 2016	Jan. 04, 2016	May. 27, 2015	Nov. 27, 2013	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 22, 2015	Dec. 07, 2015	Nov. 06, 2015	Oct. 09, 2015	Sep. 04, 2015	Dec. 19, 2014	Oct. 23, 2014	Feb. 18, 2014
Stockholders Equity Note Disclosure [Line Items]
Sales of common stock and warrants for cash									$ 2,033,700	$ 2,605,000
Warrants to purchase common stock								116,535	259,464	116,535
Warrants exercise price							$ 6	$ 6	$ 5	$ 6
Warrants aggregate grant date fair value								$ 389,608	$ 611,730	$ 389,608
Weighted average estimated fair value of stock warrants granted, per share									$ 4.07	$ 5.40
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued									31,473
Grant date fair value									$ 112,847
Common stock, Authorized	30,000,000							30,000,000	30,000,000	30,000,000
Common stock, par value								$ 0.001	$ 0.001	$ 0.001
Preferred stock, Authorized								5,000,000	5,000,000	5,000,000
Preferred stock, par value								$ 0.01	$ 0.01	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											2,250,000		2,250,000
Exercise price of redeemable warrant to be issued							$ 15
Proceeds from Warrant Exercises					$ 21,865				$ 264,144	$ 113,000
Warrant modification charge									$ 229,288	$ 50,035
Warrant redemption terms							The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $25.00 for five consecutive trading days.
Warrants excluded from computation of weighted average price of warrants granted										18,833
Stock Issued During Period, Value, Issued for Services		$ 2,420
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 4			$ 4		$ 15
Stockholders Equity Note Changes In Capital Structure Retroactive Impact Shares	200,000,000
Stockholders' Equity, Reverse Stock Split	the Company implemented a 1-for-20 reverse split
Warrants Issued During Period, Number of Warrants				15,000					125,000
Warrants Issued During Period, Exercise Price				$ 3.70					$ 5
Stock Issued During Period, Value, New Issues									$ 2,033,700	$ 2,605,000
Exercised Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants to purchase common stock									75,473
Proceeds from Warrant Exercises									$ 21,865
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 3.50
Fair Value Adjustment of Warrants									$ 20,295
Warrant One [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Outstanding									47,939
Warrant Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Outstanding									470,085
Warrant Or Right Expense Or Revenue Recognized									$ 77,905
Warrant Three [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Outstanding									75,473
Warrant Four [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Outstanding									527,308
Exercise Price Dollor Greaterthan 30.00
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted									35,000
Share based compensation shares authorized under stock option plans exercise price									$ 30
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 30
Legal Counsel
Stockholders Equity Note Disclosure [Line Items]
Grant date fair value								$ 33,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number								7,500		7,500
Professional Services
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services									943
Stock Issued During Period, Value, Issued for Services									$ 8,481
Warrants
Stockholders Equity Note Disclosure [Line Items]
Warrants to purchase common stock									125,000
Weighted average estimated fair value of stock warrants granted, per share									$ 2.72	$ 3.40
Proceeds from Warrant Exercises									$ 264,144
Stock Issued During Period, Value, New Issues									500,000
Consultant Awards | Warrants
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense									99,501	$ 185,266
Consultant Awards | Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense									$ 191,403
Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																1,000,000	1,000,000
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)									395,425	433,600
Proceeds from Warrant Exercises							$ 113,000
Minimum
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized															1,000,000	100,000,000
Preferred stock, Authorized																1,000,000
Warrants Issued During Period, Exercise Price									$ 15
Minimum | Exercised Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									4
Minimum | Warrant Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit									6
Minimum | Warrant Three [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									4
Minimum | Warrant Four [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									5
Minimum | New Warrant | Warrant Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit									4
Minimum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																		300,000
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price								$ 5	$ 4	$ 5
Estimated Forfeitures Related To Option Grants Annual Rate									0.00%
Maximum
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized															2,000,000	200,000,000
Preferred stock, Authorized																5,000,000
Warrants Issued During Period, Exercise Price								15		15
Maximum | Exercised Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 15
Maximum | Warrant Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit									20
Maximum | Warrant Three [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									15
Maximum | Warrant Four [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									20
Maximum | New Warrant | Warrant Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit									10
Maximum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																		600,000
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price								$ 9	$ 7	$ 9
Estimated Forfeitures Related To Option Grants Annual Rate									5.00%
Weighted Average [Member] | Warrant Three [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 3.50
Weighted Average [Member] | Warrant Four [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 4
Bermuda Lender [Member]
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)			27,500						50,000	22,500
Warrants to purchase common stock									12,500
Warrant modification charge						$ 80,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 15			$ 15
Stock Issued During Period, Value, New Issues									$ 300,000
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value						$ 672,056			$ 40,000

Subsequent Events- Additional I

Subsequent Events- Additional Information (Detail) - USD ($)	Mar. 07, 2016	Mar. 28, 2016	Feb. 18, 2016	Mar. 25, 2016	May. 02, 2014	Dec. 31, 2015	Dec. 31, 2014	Oct. 09, 2015	Dec. 02, 2014
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage								10.00%
Warrants Issued During Period, Number of Warrants		15,000				125,000
Warrants Issued During Period, Exercise Price		$ 3.70				$ 5
Stock Issued During Period, Value, New Issues						$ 2,033,700	$ 2,605,000
Debt Instrument, Face Amount								$ 150,000
Proceeds from Convertible Debt						$ 65,000
Warrant To Purchase Common Stock Issued In Period						259,464	116,535
Maximum
Subsequent Event [Line Items]
Warrants Issued During Period, Exercise Price							$ 15
Minimum
Subsequent Event [Line Items]
Warrants Issued During Period, Exercise Price						$ 15
Convertible Notes Payable Two
Subsequent Event [Line Items]
Repayments of Debt		$ 78,500
Convertible Notes Payable
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage						10.00%			10.00%
Proceeds from Convertible Debt					$ 175,000
Convertible Notes Payable | Maximum
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage						12.00%
Convertible Notes Payable | Minimum
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage						1.00%
Consultants
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services		18,253
Subsequent Event
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage	10.00%
Sale of Stock, Price Per Share		$ 3
Debt Instrument, Face Amount		$ 150,000
Proceeds from Convertible Debt	$ 75,000
Debt Instrument, Increase, Accrued Interest		$ 7,370
Sale of Stock, Number of Shares Issued in Transaction		52,457
Received non-interest bearing advances from officer		$ 46,030
Repayments Short Term Advances		$ 99,560
Subsequent Event | Exchange Agreement | Lender One
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		78,955
Sale of Stock, Price Per Share		$ 2.10
Debt Instrument, Face Amount		$ 160,000
Debt Instrument, Increase, Accrued Interest		$ 5,802
Subsequent Event | Warrant Exercises
Subsequent Event [Line Items]
Warrants Issued During Period, Number of Warrants		60,831
Warrants Issued During Period, Exercise Price		$ 3.50
Stock Issued During Period, Value, New Issues		$ 212,898
Subsequent Event | Warrant Modifications
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services		12,916
Subsequent Event | Maximum | Warrant Exercises
Subsequent Event [Line Items]
Warrants Issued During Period, Exercise Price		$ 15
Subsequent Event | Maximum | Warrant Modifications
Subsequent Event [Line Items]
Sale of Stock, Price Per Share		15
Subsequent Event | Minimum | Warrant Exercises
Subsequent Event [Line Items]
Warrants Issued During Period, Exercise Price		4
Subsequent Event | Minimum | Warrant Modifications
Subsequent Event [Line Items]
Sale of Stock, Price Per Share		$ 4
Subsequent Event | Convertible Notes Payable One
Subsequent Event [Line Items]
Debt Instrument, Face Amount				$ 163,000
Repayments of Debt				30,000
Debt Instrument, Periodic Payment, Principal				25,000
Debt Instrument, Fee Amount				$ 5,000
Subsequent Event | Convertible Notes Payable
Subsequent Event [Line Items]
Warrants Issued During Period, Exercise Price			$ 4
Debt Instrument, Face Amount			$ 250,000
Debt Instrument, Interest Rate, Effective Percentage			10.00%
Debt Instrument, Convertible, Terms of Conversion Feature	The convertible note is payable as follows: (i) $25,000 of principal and the respective accrued interest is payable six months from the issuance date (the First Maturity Date), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date, and (iii) $25,000 of principal and the respective accrued interest on such principal is payable one month following the First Maturity Date. Each payment of principal and the respective accrued interest is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) 62% of the fair market value of the Companys stock or (b) $2.00 per share.
Warrant To Purchase Common Stock Issued In Period			20,000
Warrants Vesting Period			5 years
Subsequent Event | Investor
Subsequent Event [Line Items]
Warrants Issued During Period, Number of Warrants		1,248,937
Stock Issued During Period, Shares, New Issues		404,593
Stock Issued During Period, Value, New Issues		$ 1,618,372
Subsequent Event | Investor | Maximum
Subsequent Event [Line Items]
Sale of Stock, Price Per Share		$ 5
Subsequent Event | Investor | Minimum
Subsequent Event [Line Items]
Sale of Stock, Price Per Share		$ 4.50